Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
U.S. declined 15% (18% in constant currency) with $30M revenue vs. $36M year-ago. Recovery to $200M+ annualized target hinges on Dahej and Indrad plant inspections/approvals—a regulatory timing risk. Management declined to quantify one-off impacts from product exits.
While management argues 4% AIOCD growth understates real market (7-8%), analyst Saion Mukherjee challenged whether trade generics, Jan Aushadhi, and private labels represent a structural shift dragging growth from historical 10% to 7-8%. Management called this risk 'overestimated' but acknowledged ~0.5% IPM impact possible.
Analyst raised government initiatives to push doctors toward writing generic names. Management noted quality infrastructure gaps exist but predicted branded generics will persist in hybrid system. No specific mitigation announced for potential policy-driven market share erosion.
Multiple analysts probed capital allocation and M&A priorities; CFO deflected, declining to comment on valuation targets, deal size philosophy, or whether management seeks to be top-5 vs. top-10 Indian pharma. Comfortable starting leverage of 3x (declining to 1.5-2x) stated but no specific acquisition pipeline disclosed.
